Review
Oncology
Qingdan Gu, Jiazhen Zou, Ying Zhou, Qiuchan Deng
Summary: Inflammasomes, composed of NOD-like receptors (NLRs), play an important role in the host defense mechanism by sensing PAMPs and DAMPs. They activate inflammatory signaling pathways and produce proinflammatory cytokines, which are associated with cancer. Furthermore, inflammasomes can promote tumor progression by creating tumor-supportive microenvironments, promoting tumor cell proliferation, and inhibiting apoptosis. Therefore, targeting inflammasomes and proinflammatory cytokines with novel drugs is a promising approach for cancer treatment, with several natural extracts and synthetic small molecules currently under investigation.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Hans-Georg Wirsching, Michael Weller, Stefan Balabanov, Patrick Roth
Summary: Primary central nervous system lymphoma is a rare disease with limited treatment options, but emerging strategies include small molecule inhibitors, immunomodulatory agents, and immune checkpoint inhibitors. This review article discusses mechanisms, clinical study results, ongoing trials, and future prospects for these developments in CNS lymphoma treatment.
Review
Oncology
Erica Brivio, Andre Baruchel, Auke Beishuizen, Jean-Pierre Bourquin, Patrick A. Brown, Todd Cooper, Lia Gore, E. Anders Kolb, Franco Locatelli, Shannon L. Maude, Francis J. Mussai, Britta Vormoor-Burger, Josef Vormoor, Arend von Stackelberg, C. Michel Zwaan
Summary: Despite improvements in treating newly diagnosed leukaemia and lymphoma in children, refractory or relapsed cases remain difficult to manage. Novel agents that offer less toxicity while maintaining efficacy are being explored. However, drug development for paediatric cancers lags behind adult therapeutic options.
EUROPEAN JOURNAL OF CANCER
(2022)
Review
Oncology
Anagha Deshpande, Javier Munoz
Summary: The therapeutic landscape for lymphomas is diverse, including targeted therapies, but tumor cells often develop multiple resistance mechanisms to these treatments.
FRONTIERS IN ONCOLOGY
(2022)
Review
Pharmacology & Pharmacy
Danielle Wallace, Patrick M. Reagan
Summary: Mantle cell lymphoma is a rare and incurable lymphoma, currently being targeted with therapies addressing dysregulation of B-cell signaling pathways to improve prognosis. Recent studies have shown successful treatment outcomes with novel drugs in the relapsed/refractory population.
Review
Oncology
Maria Christina Cox, Guido Bocci
Summary: Novel drugs are changing the treatment approach for non-Hodgkin lymphomas, with chemotherapy still being a key part of treatment for aggressive subtypes. Metronomic chemotherapy, involving long-term low dose drug administration, shows potential for more effective and tolerable combinations. This approach has been little explored in NHLs but has shown promising results in pre-clinical studies.
Review
Oncology
Jennifer Girard, Yasmin Karimi, Shannon Carty, Ryan Wilcox, Mark Kaminiski, Sami Malek, Tycel Phillips
Summary: Follicular lymphoma is the second most common type of lymphoma in the USA and Western Europe, with various treatment options available. Recent advances in treatment, including the introduction of new agents such as CD20 antibody rituximab, have significantly improved treatment outcomes for patients. Additionally, more targeted therapies have shown promising results, providing hope for future advancements in finding a cure for this incurable disease.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS
(2021)
Article
Biochemistry & Molecular Biology
Chantale Farah, Marie-Aline Neveu, Caner Yelek, Caroline Bouzin, Bernard Gallez, Jean-Francois Baurain, Lionel Mignion, Benedicte F. Jordan
Summary: This study evaluated the metabolic changes in melanoma in response to BRAF/MEK inhibition and identified C-13-glucose metabolism as a potential marker of treatment response.
Article
Oncology
Chi Yan, Caroline A. Nebhan, Nabil Saleh, Rebecca Shattuck-Brandt, Sheau-Chiann Chen, Gregory D. Ayers, Vivian Weiss, Ann Richmond, Anna E. Vilgelm
Summary: Humanized PDX mouse models with reduced development of GVHD were generated, allowing for preclinical trials with immune checkpoint inhibitors.
Article
Biology
Priya Saikumar Lakshmi, Cliff Oduor, Catherine S. Forconi, Viriato M. ' Bana, Courtney Bly, Rachel M. Gerstein, Juliana A. Otieno, Christian Muenz, Micah A. Luftig, Michael A. Brehm, Jeffrey A. Bailey, Ann M. Moormann, John M. Ong'echa
Summary: Endemic Burkitt lymphoma (BL), characterized by Epstein-Barr virus and malaria associated aberrant B-cell activation and MYC chromosomal translocation, is a childhood cancer in sub-Saharan Africa. Conventional chemotherapies have limited efficacy, thus the need for clinically relevant models to test additional therapies. This study established patient-derived BL tumor cell lines and corresponding NSG-BL avatar mouse models, which were shown to maintain fidelity to patient tumors. Significant variation in tumor growth, survival, and Epstein-Barr virus protein expression patterns were observed among the NSG-BL avatars. The findings highlight the importance of these models in guiding new therapeutic strategies for improving outcomes in children with BL.
LIFE SCIENCE ALLIANCE
(2023)
Article
Hematology
Salome Decombis, Celine Bellanger, Yannick Le Bris, Candice Madiot, Jane Jardine, Juliana Carvalho Santos, Delphine Boulet, Christelle Dousset, Audrey Menard, Charlotte Kervoelen, Elise Douillard, Philippe Moreau, Stephane Minvielle, Agnes Moreau-Aubry, Benoit Tessoulin, Gael Roue, Nicolas Bidere, Steven Le Gouill, Catherine Pellat-Deceunynck, David Chiron
Summary: This study identified the resistance mechanisms to targeted therapies in B-cell lymphomas and proposed a novel strategy to overcome this resistance. The study also discovered a resistance signature that could predict the response to conventional chemotherapy.
Review
Clinical Neurology
Isaias Hernandez-Verdin, Andrea Morales-Martinez, Khe Hoang-Xuan, Agusti Alentorn
Summary: Recent studies have revealed four distinct molecular subtypes of PCNSL with prognostic relevance, highlighting the importance of the tumor microenvironment (TME) as a driving prognostic factor. Therapeutic efforts are focused on targeting the NF-kappa beta pathway or modulating the TME through immunomodulatory drugs or immunotherapy. Further research is needed to develop diagnostic biomarkers for detecting PCNSL and its molecular subtypes in routine clinical use.
CURRENT OPINION IN NEUROLOGY
(2022)
Article
Oncology
Elisa Genuardi, Petra Klous, Barbara Mantoan, Daniela Drandi, Martina Ferrante, Federica Cavallo, Beatrice Alessandria, Irene Dogliotti, Daniele Grimaldi, Simone Ragaini, Michele Clerico, Mariella Lo Schirico, Elona Saraci, Mehmet Yilmaz, Gian Maria Zaccaria, Sergio Cortelazzo, Umberto Vitolo, Stefano Luminari, Massimo Federico, Mario Boccadoro, Max van Min, Erik Splinter, Marco Ladetto, Simone Ferrero
Summary: Targeted locus amplification (TLA) is a promising next-generation sequencing (NGS) technology that can identify novel molecular markers in previously untraceable mantle cell lymphoma (MCL) and follicular lymphoma (FL) patients, offering potential for further minimal residual disease (MRD) analysis.
HEMATOLOGICAL ONCOLOGY
(2021)
Review
Oncology
Huimin Ma, Xin Li, Meng Lin, Kebing Lv, Mingzhi Zhang, Xiaolong Wu
Summary: The current standard treatment for relapsed or refractory HL is salvage chemotherapy followed by ASCT, but it may not be successful for all patients. New treatment options including targeted therapy and immunotherapy, such as BV and anti-PD-1 antibodies, have shown effectiveness in treating these patients. BV and anti-PD-1 antibodies can be used alone or in combination with other chemotherapy regimens for rescue, consolidation, and second-line treatment of R/R HL.
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
(2021)
Review
Oncology
Adam S. S. DuVall, Austin Wesevich, Richard A. A. Larson
Summary: This review focuses on the treatment advances in relapsed and/or refractory acute lymphoblastic leukemia (ALL), mainly in B cell disease. Recent understanding of T-ALL biology and improvement in immunotherapies have led to new therapeutic pathways. The review highlights the potential of targeting different pathways and explores other therapeutic possibilities for T-ALL.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS
(2023)
Article
Oncology
Paola Chiodelli, Daniela Coltrini, Marta Turati, Marianna Cerasuolo, Federica Maccarinelli, Sara Rezzola, Elisabetta Grillo, Arianna Giacomini, Sara Taranto, Silvia Mussi, Alessia Ligresti, Marco Presta, Roberto Ronca
Summary: The study validates the therapeutic efficacy of the FDA-approved FGFR inhibitor pemigatinib in treating PCa and CRPC, and reveals its synergistic effect with enzalutamide in inhibiting tumor growth, providing valuable data support for the clinical application of this treatment approach.
Review
Gastroenterology & Hepatology
Daniele Piovani, Cesare Hassan, Alessandro Repici, Lorenza Rimassa, Carmelo Carlo-Stella, Georgios K. Nikolopoulos, Elio Riboli, Stefanos Bonovas
Summary: This study summarized the epidemiologic evidence and validity of associations between inflammatory bowel diseases (IBDs) and overall and site-specific cancer risk. The results showed varying levels of evidence and magnitude of risk for different types of malignancy. Further research is needed to investigate the impact of risk factors known to affect cancer risk.
Letter
Hematology
Juan P. Alderuccio, Weiyun Z. Ai, John Radford, Melhem Solh, Kirit M. Ardeshna, Matthew A. Lunning, Brian T. Hess, Pier L. Zinzani, Anastasios Stathis, Carmelo Carlo-Stella, Mehdi Hamadani, Brad S. Kahl, David Ungar, Turk Kilavuz, Eric Yu, Yajuan Qin, Paolo F. Caimi
Article
Oncology
Carmelo Carlo-Stella, Pier Luigi Zinzani, Anna Sureda, Luis Araujo, Olivier Casasnovas, Cecilia Carpio, Su-Peng Yeh, Krimo Bouabdallah, Guillaume Cartron, Won Seog Kim, Raul Cordoba, Youngil Koh, Alessandro Re, Daniela Alves, Martine Chamuleau, Steven Le Gouill, Armando Lopez-Guillermo, Ilidia Moreira, Marjolein W. M. van der Poel, Giovanni Abbadessa, Robin Meng, Ran Ji, Lucie Lepine, Rao Saleem, Vincent Ribrag
Summary: This study evaluated the safety, efficacy, and pharmacokinetics of a combination treatment of Cemi (anti-PD-1 receptor antibody) and Isa (anti-CD38 antibody) in patients with relapsed or refractory lymphoma. The results showed that the combination treatment had manageable safety and modest clinical efficacy in patients with cHL, DLBCL, and PTCL.
HEMATOLOGICAL ONCOLOGY
(2023)
Meeting Abstract
Hematology
Martin Hutchings, Carmelo Carlo-Stella, Franck Morschhauser, Emmanuel Bachy, Paolo Corradini, Gloria Iacoboni, Cyrus Khan, Krish Patel, Mark Hertzberg, Lorenzo Falchi, Nancy L. Bartlett, Joshua Brody, Linda Lundberg, Yuying Xie, Estefania Mulvihill, Pauline Baumlin, James Relf, Emily Piccione, Kathryn Humphrey, Michael Dickinson
Meeting Abstract
Hematology
Martin Hutchings, Carmelo Carlo-Stella, Giuseppe Gritti, Francesc Bosch, Franck Morschhauser, William Townsend, Fritz Offner, Harriet S. Walter, Herve Ghesquieres, Roch Houot, Guillaume Cartron, Natalie Dimier, Stephen Fowler, Emma Harrop, Sylvia Herter, Abiraj Keelara, Koorosh Korfi, Jeff Luong, Claudia Mueller, Robert Nutbrown, Giuseppe Palldino, Matt Whayman, Isabel Prieto, Sarah Louise Mycroft, Daria Rukina, Katharina E. Lechner, Michael Dickinson
Meeting Abstract
Hematology
Carmelo Carlo-Stella, Rita Mazza, Salomon Manier, Thierry Facon, Sung-Soo Yoon, Youngil Koh, Simon J. Harrison, Jeremy Er, Antonio Pinto, Francesco Volzone, Giulia Perrone, Paolo Corradini, Titouan Cazaubiel, Cyrille Hulin, Cyrille Touzeau, Philippe Moreau, Enrique M. Ocio, Carmen Maria Montes Gaisan, Rakesh Popat, Sarah Leong, Fritz Offner, Paula Rodriguez Otero, Ana Alfonso-Pierola, Ann-Marie E. Broeske, Iryna Dekhtiarenko, Hans-Joachim Helms, Sara Belli, Eva Rossmann, Tanja Fauti, Jan Eckmann, Tom Moore, Meike Schneider, Wolfgang Jacob, Martin Weisser, Martin Hutchings, Caroline Hasselbalch Riley
Article
Oncology
Alexander Lesokhin, Richard LeBlanc, Meletios A. Dimopoulos, Marcelo Capra, Carmelo Carlo-Stella, Lionel Karlin, Jean-Francois Castilloux, Peter Forsberg, Gurdeep Parmar, Axel Tosikyan, Ludek Pour, Vincent Ribrag, Rossella Ribolla, Al-Ola Abdallah, Nadia Le Roux, Liyan Dong, Helgi van de Velde, Laurent Mayrargue, Lucie Lepine, Sandrine Mace, Philippe Moreau
Summary: This study aimed to determine whether cemiplimab enhances the anti-myeloma activity of isatuximab in RRMM patients and evaluate its safety. The results showed that although the combination of cemiplimab and isatuximab had a certain effect in patients, the differences were not statistically significant and did not improve progression-free or overall survival. Therefore, adding cemiplimab to the isatuximab treatment regimen only has marginal benefits.
Article
Oncology
Damiano Dei, Nicola Lambri, Sara Stefanini, Veronica Vernier, Ricardo Coimbra Brioso, Leonardo Crespi, Elena Clerici, Luisa Bellu, Chiara De Philippis, Daniele Loiacono, Pierina Navarria, Giacomo Reggiori, Stefania Bramanti, Marcello Rodari, Stefano Tomatis, Arturo Chiti, Carmelo Carlo-Stella, Marta Scorsetti, Pietro Mancosu
Summary: The contouring of lymph node clinical target volume (CTV_LN) in total marrow and lymph node irradiation (TMLI) is complex and time-consuming. The introduction of internal guidelines reduced inter- and intraobserver variability in CTV_LN delineation. The guidelines improved the consistency of contouring in TMLI treatments.
Article
Oncology
Nicola Lambri, Simone Leopoldo Antonetti, Damiano Dei, Luisa Bellu, Stefania Bramanti, Ricardo Coimbra Brioso, Carmelo Carlo-Stella, Isabella Castiglioni, Elena Clerici, Leonardo Crespi, Chiara De Philippis, Carmela Galdieri, Daniele Loiacono, Pierina Navarria, Giacomo Reggiori, Roberto Rusconi, Stefano Tomatis, Marta Scorsetti, Pietro Mancosu
Summary: Delivery of total marrow (lymph node) irradiation (TMI/TMLI) takes longer than standard radiotherapy treatments due to patient's extremity movements. The study evaluated the reproducibility of TMI/TMLI patient's extremities in order to find the best positioning and minimize unwanted movements.
Meeting Abstract
Oncology
Mehdi Hamadani, Christopher Graham, Laura Liao, Kate Zhang, Hannah Strat, David Ungar, Weiyun Ai, Lei Chen, Carmelo Carlo-Stella
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2022)
Meeting Abstract
Oncology
M. Dreyling, T. Phillips, M. Dickinson, F. Morschhauser, E. Bachy, M. Crump, M. Trneny, N. Bartlett, J. Zaucha, K. Humphrey, D. Perez-Callejo, L. Lundberg, J. Relf, De L'Etang A. Filezac, D. Carlile, E. Clark, C. Carlo-Stella
ONCOLOGY RESEARCH AND TREATMENT
(2022)
Meeting Abstract
Oncology
M. Hutchings, M. Dickinson, C. Carlo-Stella, F. Morschhauser, E. Bachy, P. Corradini, G. Iacoboni, C. Khan, T. Wrobel, F. Offner, M. Trneny, S. -J. Wu, G. Cartron, M. Hertzberg, A. Sureda, D. Perez-Callejo, L. Lundberg, J. Relf, E. Clark, K. Humphrey
ONCOLOGY RESEARCH AND TREATMENT
(2022)
Meeting Abstract
Oncology
Anna Maria Di Giacomo, Federica Santangelo, Giovanni Amato, Elena Simonetti, Jill Graham, Michael M. F. Lahn, Lars Anders Van der Veen, Zoe Johnson, Catherine Anne Pickering, Marco Durini, Ziyang Tan, Lakshmikanth Tadepally, Petter Brodin, Mariaelena Occhipinti, Matteo Simonelli, Carmelo Carlo-Stella, Armando Santoro, Pavlina Spiliopoulou, T. R. Jeffry Evans, Michele Maio
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Michael Dickinson, Carmelo Carlo-Stella, Franck Morschhauser, Emmanuel Bachy, Paolo Corradini, Gloria Iacoboni, Cyrus Khan, Tomasz Wrobel, Fritz Offner, Marek Trneny, Shang-Ju Wu, Guillaume Cartron, Mark Hertzberg, Anna Sureda Balari, David Perez-Callejo, Linda Lundberg, James Relf, Emma Clark, Kathryn Humphrey, Martin Hutchings
JOURNAL OF CLINICAL ONCOLOGY
(2022)